NIH Highlighted Topic: Breaking Barriers: Integrating Immunology and Neuroscience to Transform AD/ADRD Research and Bring a Better Understanding of the Aging Brain

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on integrating immunology, neuroscience, and aging research to transform understanding, prevention, diagnosis, and treatment of Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD). This highlighted topic supports multidisciplinary projects investigating how immune system dysfunction, neuroinflammation, infections, autoimmunity, environmental exposures, and aging-related immune changes contribute to neurodegeneration and cognitive decline.

NIH is particularly interested in projects that bridge traditionally separate disciplines — including immunology, neuroscience, infectious disease, computational biology, and environmental health — to uncover novel mechanisms underlying AD/ADRD pathogenesis. Companies developing neuroimmunology platforms, AI-enabled biomarker systems, precision diagnostics, computational modeling tools, organoid systems, immunotherapeutics, microbiome analytics platforms, or neurodegenerative disease monitoring technologies may be strong candidates for funding.

Areas of interest include neuroimmune crosstalk, innate and adaptive immune dysfunction, immunosenescence, neuroinflammation, infectious disease interactions, autoimmunity, microbiome effects, exposome-related neurotoxicity, environmental exposure modeling, biomarker discovery, risk stratification, and immunotherapeutic development. NIH is also encouraging projects leveraging organoids, microphysiological systems, human tissues, AI and machine learning, computational neuroscience, and translational model systems to improve understanding of aging brain biology and AD/ADRD progression.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by the National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), and National Institute of Environmental Health Sciences (NIEHS), all of which are seeking transformative innovations that improve neurodegenerative disease diagnostics, immune-based therapies, environmental health understanding, and precision approaches to Alzheimer’s disease and aging brain research.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of neuroimmunology technologies, biomarkers, computational systems, diagnostics, immunotherapies, and translational neuroscience platforms related to AD/ADRD and aging brain research.

Eligible activities may include:

• AI and machine learning platforms for AD/ADRD biomarker discovery and risk prediction

• Neuroimmune interaction and neuroinflammation research technologies

• Immunotherapeutic and vaccine development platforms for neurodegenerative diseases

• Organoid, microphysiological, and human tissue modeling systems

• Computational neuroscience and neuroimmunology simulation platforms

• Microbiome and infectious disease analytics related to neurodegeneration

• Precision diagnostics and early detection technologies for Alzheimer’s disease

• Immunophenotyping and immune-aging monitoring systems

• Environmental exposure and exposome analytics platforms

• Autoimmunity and neurodegeneration biomarker research tools

• Longitudinal cognitive monitoring and digital health assessment systems

• Translational neuroscience and neurodegenerative disease modeling technologies

• Predictive analytics for cognitive decline and disease progression

• Behavioral, social, and environmental factor integration platforms

• Multi-omics and systems biology technologies for aging brain research

• Novel therapeutic target discovery and validation systems

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, laboratory testing, software engineering, cloud infrastructure, AI model development, computational modeling, bioinformatics analysis, preclinical studies, organoid research, environmental health analytics, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable neuroscience or biotechnology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Research on Chatbots and their Usage

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding the benefits, harms, safety, and long-term impacts of conversational chatbot technologies in healthcare and health-related settings. This highlighted topic supports multidisciplinary projects designed to rigorously evaluate how chatbot design, personalization, safeguards, and patterns of use influence health outcomes, clinical decision-making, autonomy, behavior, and trust across diverse populations and real-world contexts.

NIH recognizes that chatbots are increasingly used for symptom interpretation, chronic disease management, mental health support, caregiving, treatment decision-making, health information access, and social interaction — often without professional oversight. The initiative is particularly interested in projects that move beyond proof-of-concept to investigate causal mechanisms, unintended consequences, misinformation risks, automation bias, dependency, delayed professional care, and safe deployment practices.

Companies developing healthcare chatbots, AI safety platforms, conversational AI systems, digital therapeutics, clinical decision support tools, chatbot evaluation frameworks, governance systems, behavioral analytics platforms, or AI monitoring technologies may be strong candidates for funding.

Areas of interest include chatbot safety benchmarking, longitudinal user behavior analysis, AI transparency, guardrails and escalation systems, misinformation mitigation, mental health and substance use chatbot interventions, cancer care support tools, chatbot-human clinical integration, explainable AI systems, conversational AI for older adults and caregivers, and responsible AI frameworks aligned with healthcare interoperability standards such as FHIR and SMART on FHIR.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including NIA, NCCIH, NCI, NIDA, NIDCR, NIMH, NLM, OBSSR, and ODSS, all of which are seeking transformative innovations that improve safe, ethical, evidence-based deployment of conversational AI and chatbot technologies in healthcare and public health environments.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of healthcare chatbot technologies, AI safety systems, conversational AI governance platforms, behavioral analytics tools, and clinical decision support solutions.

Eligible activities may include:

• Healthcare chatbot and conversational AI platform development

• AI safety monitoring, guardrails, and escalation systems

• Chatbot benchmarking, validation, and misinformation detection frameworks

• Clinical decision support and symptom interpretation technologies

• Mental health, substance use disorder, and behavioral health chatbot systems

• Cancer care support, patient education, and survivorship chatbot platforms

• Longitudinal user engagement and dependency analytics systems

• Explainable AI, transparency, and responsible AI governance tools

• Conversational AI systems for older adults, caregivers, and vulnerable populations

• AI-enabled risk stratification and safety monitoring technologies

• Digital therapeutics and chatbot-assisted intervention platforms

• FHIR, SMART on FHIR, and healthcare interoperability integration systems

• Behavioral and social science analytics related to chatbot usage patterns

• Human-centered AI design and co-development frameworks

• Clinical workflow integration and provider oversight systems

• Privacy-preserving conversational AI and secure data-sharing infrastructure

• Prototype development, translational studies, and real-world validation research

• Commercialization planning, regulatory preparation, and implementation scaling activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, cybersecurity systems, user research, behavioral analytics, implementation science, interoperability integration, stakeholder engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare AI or conversational technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Strengthening Biomedical Research, Promoting Trust, and Improving Health through Bioethics Research

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on strengthening biomedical research, improving public trust in science, and advancing actionable bioethics research across biomedical, behavioral, clinical, and data-driven health research ecosystems. This highlighted topic supports multidisciplinary projects designed to integrate ethical principles into emerging technologies, artificial intelligence, genomics, neuroscience, clinical trials, digital health, and data science to improve transparency, autonomy, equity, and long-term public engagement in research.

NIH is particularly interested in projects that address ethical challenges related to AI systems, digital health technologies, informed consent, data sharing, community engagement, participant autonomy, return of research results, privacy, neurotechnology, genomics, and biomedical innovation. Companies developing AI governance platforms, healthcare consent systems, ethical data-sharing infrastructure, digital health ethics tools, research engagement technologies, privacy-preserving analytics systems, or bioethics-focused clinical research platforms may be strong candidates for funding.

Areas of interest include AI transparency and generalizability, ethical design of neurotechnology and biomedical AI systems, genomic privacy, informed consent for wearables and electronic health records, community-centered clinical trial recruitment, ethical use of imaging and biometrics, return-of-results frameworks, health equity, data security, responsible AI deployment, implementation science, and trust-building approaches for underserved and vulnerable populations.

Funding is available through the NIH SBIR/STTR Program and related NIH research mechanisms, with opportunities for Phase I and Phase II commercialization support depending on project scope and translational impact.

This highlighted topic is supported by numerous NIH Institutes and Offices including OSP, BRAIN Initiative, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NIDA, NIDCR, NINDS, ODSS, OBSSR, and others, all of which are seeking transformative innovations that strengthen ethical biomedical research, trustworthy AI, responsible data use, participant engagement, and equitable healthcare innovation.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of bioethics technologies, AI governance systems, informed consent platforms, data privacy tools, and community-engagement solutions for biomedical research and healthcare innovation.

Eligible activities may include:

• AI governance, transparency, and explainability platforms for healthcare and biomedical research

• Ethical data-sharing and privacy-preserving analytics systems

• Digital informed consent and participant autonomy technologies

• Community engagement and clinical trial recruitment platforms

• Ethical AI and neurotechnology assessment tools

• Genomics, imaging, and biometric privacy infrastructure

• Return-of-results communication and decision-support systems

• Research trust-building and public engagement technologies

• Data stewardship and FAIR/CARE-aligned research infrastructure

• Bioethics analytics and compliance monitoring systems

• Ethical frameworks for wearables, EHRs, linked data, and public health research

• AI bias detection and generalizability validation platforms

• Clinical trial transparency and adaptive research governance technologies

• Neuroethics and brain-computer interface ethics platforms

• Digital health ethics, implementation science, and health equity technologies

• Educational and workforce development tools supporting responsible biomedical innovation

• Prototype development, translational studies, and implementation research

• Commercialization planning, regulatory preparation, and deployment scaling activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, cybersecurity systems, community-engaged research, data governance implementation, usability testing, stakeholder engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable bioethics or healthcare technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Health and Extreme Weather: Advancing Critical Research to Address the Direct and Indirect Health Impacts of Weather-Related Natural Disasters.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding, preventing, and mitigating the direct and indirect health impacts of extreme weather events and weather-related natural disasters. This highlighted topic supports multidisciplinary projects designed to improve resilience, strengthen healthcare preparedness, develop evidence-based interventions, and better understand how environmental and meteorological exposures influence human health across the lifespan.

The NIH Health and Extreme Weather (HEW) Program is particularly interested in research addressing health risks associated with heatwaves, floods, hurricanes, droughts, wildfires, harmful algal blooms, extreme storms, humidity, air pollution, and other downstream environmental exposures influenced by weather-related phenomena. Companies developing environmental health technologies, climate-health analytics platforms, AI-enabled predictive systems, remote sensing technologies, wearable exposure monitoring tools, public health infrastructure systems, telehealth platforms, or resilience-focused healthcare technologies may be strong candidates for funding.

Areas of interest include environmental exposure modeling, population health surveillance, community resilience interventions, implementation science, disaster preparedness systems, longitudinal health monitoring, environmental data integration, wearable sensors, behavioral health interventions, healthcare continuity technologies, and predictive analytics related to weather-driven disease risks. NIH is also encouraging projects focused on vulnerable populations including children, older adults, pregnant women, first responders, rural populations, outdoor workers, cancer patients, and individuals with chronic health conditions.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by numerous NIH Institutes and Offices including NIEHS, NHLBI, NIA, NIAID, NIMH, NIMHD, NINR, NCI, NIAMS, NCCIH, ODP, ORWH, and OBSSR, all of which are seeking transformative innovations that improve climate resilience, environmental health monitoring, healthcare preparedness, and population health outcomes related to extreme weather.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of climate-health technologies, environmental monitoring systems, predictive analytics platforms, public health tools, and resilience-focused healthcare solutions.

Eligible activities may include:

• AI and machine learning platforms for extreme weather health risk prediction

• Environmental exposure monitoring and wearable sensor technologies

• Climate-health analytics and population surveillance systems

• Public health preparedness and disaster response technologies

• Telehealth and healthcare continuity platforms during natural disasters

• Environmental data integration and exposome analytics systems

• Community resilience and implementation science intervention platforms

• Heat stress, wildfire smoke, air pollution, and environmental toxin monitoring tools

• Predictive modeling for infectious disease, respiratory illness, and chronic disease exacerbation

• Remote patient monitoring for vulnerable and high-risk populations

• Behavioral health and mental health intervention systems related to disaster exposure

• Rural and underserved community healthcare infrastructure technologies

• Environmental justice and health disparities intervention platforms

• Cancer survivorship, cardiovascular, respiratory, and neurological resilience technologies

• Data interoperability and longitudinal climate-health research infrastructure

• Natural disaster recovery and healthcare systems coordination tools

• Prototype development, translational studies, and implementation research

• Commercialization planning, regulatory preparation, and deployment scaling activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, environmental sensing hardware, epidemiological analysis, implementation science research, healthcare systems integration, community engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable environmental health or healthcare technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Quantum Information Science & Technologies for Biomedical Applications

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on applying Quantum Information Science (QIS) and quantum technologies to biomedical research, diagnostics, imaging, sensing, therapeutics, and computational biology. This highlighted topic supports multidisciplinary projects aimed at leveraging quantum physics principles to dramatically improve the precision, sensitivity, speed, and scalability of biomedical technologies and healthcare systems.

NIH is particularly interested in projects that integrate quantum technologies with classical biomedical systems to enable breakthroughs in disease detection, physiological sensing, biomolecular simulation, imaging, computational modeling, and therapeutic discovery. Companies developing quantum sensing platforms, quantum-enhanced imaging systems, quantum computing software, hybrid quantum-classical AI systems, biointerfaces, microfluidics, or advanced biomedical diagnostics may be strong candidates for funding.

Areas of interest include quantum-enhanced imaging, quantum biosensing, lab-on-a-chip diagnostics, quantum algorithms for biomolecular simulation, quantum computing for therapeutic discovery, optoelectronic biointerfaces, neural sensing technologies, quantum-enabled AI and predictive analytics, personalized medicine platforms, and translational quantum biomedical systems. NIH is also encouraging projects focused on portability, scalability, reproducibility, benchmarking against classical systems, and integration with clinical workflows and biomedical data infrastructures.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including NIBIB, BRAIN Initiative, NCATS, NCI, NEI, NHLBI, NIDCR, NIGMS, and ODSS, all of which are seeking transformative innovations that advance quantum-enabled healthcare technologies, diagnostics, computational biology, imaging systems, and biomedical research infrastructure.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of quantum biomedical technologies, quantum computing platforms, sensing systems, imaging tools, diagnostics, and computational biology solutions.

Eligible activities may include:

• Quantum-enhanced biomedical imaging systems

• Quantum biosensing and ultrasensitive diagnostic platforms

• AI-enabled hybrid quantum-classical computational systems

• Quantum algorithms for biomolecular simulation and therapeutic discovery

• Quantum-enabled lab-on-a-chip and microfluidic diagnostic technologies

• Optoelectronic biointerfaces for physiological monitoring and modulation

• Quantum sensing systems for neural recording and neuromodulation

• Portable quantum diagnostics and point-of-care testing platforms

• Quantum imaging for cancer, cardiovascular, neurological, ocular, and craniofacial diseases

• Hyperpolarized MRI, photon-counting CT, and quantum optical coherence tomography technologies

• Quantum computing platforms for predictive analytics and personalized medicine

• Wearable and implantable quantum-enabled biomedical devices

• Biomedical data integration and quantum-enabled AI/ML infrastructure

• Real-time biomarker detection and physiological monitoring systems

• Translational quantum technologies integrated into clinical workflows

• Benchmarking, reproducibility, and scalability frameworks for quantum biomedical systems

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, software engineering, quantum hardware development, cloud computing infrastructure, AI model development, laboratory testing, computational modeling, biomedical imaging research, device prototyping, bioinformatics analysis, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable quantum healthcare or biomedical technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Enhancing Scientific Rigor, Transparency and Replicability

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on improving scientific rigor, transparency, reproducibility, and replicability across the biomedical research enterprise. This highlighted topic supports multidisciplinary projects that develop new tools, standards, methodologies, training programs, AI-enabled systems, and collaborative frameworks designed to strengthen the quality, validity, and reliability of scientific research outcomes.

NIH recognizes that reproducible and transparent research practices are essential for accelerating biomedical discovery, improving translational success, reducing bias, and maximizing public trust in science. The initiative is particularly interested in technologies and strategies that improve experimental design, metadata quality, protocol standardization, analytical reproducibility, AI validation, data interoperability, and dissemination of rigorous scientific practices.

Companies developing AI-driven research platforms, scientific workflow software, reproducibility analytics systems, metadata infrastructure, laboratory automation tools, benchmarking frameworks, biomedical informatics systems, open science technologies, or research collaboration platforms may be strong candidates for funding.

Areas of interest include AI-assisted rigor assessment, FAIR and TRUST-aligned data standards, automated metadata generation, reproducibility benchmarking, workflow traceability, protocol sharing, sex as a biological variable (SABV) frameworks, community-based training systems, common data elements (CDEs), multimodal data harmonization, laboratory automation, digital provenance tracking, and implementation science approaches that improve adoption of rigorous research practices. NIH is also encouraging projects supporting reproducibility in genomics, neuroscience, mental health, environmental health, imaging, clinical trials, aging, substance use research, and AI/ML evaluation frameworks.

Funding is available through the NIH SBIR/STTR Program and related NIH research, education, and conference mechanisms, including opportunities for Phase I and Phase II commercialization support depending on project scope and translational impact.

This highlighted topic is supported by a broad coalition of NIH Institutes and Offices including NINDS, NLM, NIBIB, NHGRI, NCI, NHLBI, NIA, NIMH, NIDA, NIAID, NEI, NCCIH, ORWH, ODSS, ODP, ODS, NIGMS, NIEHS, and many others, all of which are seeking scalable innovations that improve scientific validity, transparency, interoperability, and translational reliability across biomedical research.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of scientific rigor technologies, AI-enabled research infrastructure, reproducibility analytics platforms, metadata systems, and biomedical data science tools.

Eligible activities may include:

• AI and machine learning systems for assessing research rigor and reproducibility

• Automated protocol standardization and metadata generation platforms

• FAIR and TRUST-aligned data interoperability infrastructure

• Scientific workflow traceability and provenance tracking technologies

• Benchmarking and validation frameworks for AI/ML models

• Open science and collaborative research platforms

• Common data element (CDE) development and harmonization systems

• Biomedical informatics and multimodal data integration tools

• Laboratory automation and digital workflow capture technologies

• Research reproducibility analytics and variability assessment systems

• Clinical trial design optimization and statistical rigor tools

• Sex as a biological variable (SABV) reporting and analysis platforms

• Genomics, imaging, neuroscience, and environmental health reproducibility tools

• Community training, workforce development, and educational technologies

• Replication study infrastructure and scientific quality assurance systems

• Protocol sharing, versioning, and computational pipeline documentation platforms

• Prototype development, translational studies, and validation research

• Commercialization planning, implementation scaling, and regulatory preparation activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, biomedical data analysis, implementation science, standards development, stakeholder engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable scientific infrastructure or biomedical research technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: GLP-1s: Implications for Nutritional Status and Metabolic Health Outcomes

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding how GLP-1 receptor agonists (GLP-1s) impact nutritional status, metabolism, chronic disease outcomes, and population health. This highlighted topic supports multidisciplinary projects designed to investigate the biological, behavioral, clinical, and societal implications of rapidly expanding GLP-1 use, including both prescription therapies and dietary supplements marketed as “GLP-1 mimetics.”

NIH is particularly interested in research examining how GLP-1 therapies influence nutrient metabolism, body composition, appetite regulation, gastrointestinal function, microbiome composition, metabolic biomarkers, and long-term health outcomes. Companies developing AI-enabled nutrition analytics platforms, metabolic monitoring systems, digital therapeutics, wearable health technologies, precision nutrition platforms, dietary supplement testing systems, or real-world evidence platforms may be strong candidates for funding.

Areas of interest include metabolic health biomarkers, obesity and diabetes management, cancer prevention and survivorship, cardiovascular risk reduction, aging and cognitive outcomes, musculoskeletal health, ocular disease mechanisms, oral health effects, microbiome changes, and lifestyle interventions supporting GLP-1 treatment. NIH is also encouraging projects focused on the safety, composition, efficacy, and biological mechanisms of supplements marketed as GLP-1 mimetics, including interactions with prescription GLP-1 medications.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by numerous NIH Institutes and Offices including ODS, NCI, NEI, NHLBI, NIA, NIAMS, NIDCR, NIDDK, NINR, ODP, ONR, and OBSSR, all of which are seeking transformative innovations that improve metabolic health, nutrition science, chronic disease prevention, precision medicine, and evidence-based GLP-1 treatment strategies.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of metabolic health technologies, nutrition science platforms, AI analytics systems, digital therapeutics, biomarker tools, and dietary supplement evaluation technologies related to GLP-1 therapies and metabolic outcomes.

Eligible activities may include:

• AI and machine learning platforms for GLP-1 treatment optimization and metabolic monitoring

• Precision nutrition and personalized dietary intervention technologies

• Biomarker discovery and metabolic risk prediction systems

• Wearable devices and remote monitoring technologies for nutrition and body composition

• Digital therapeutics supporting GLP-1 adherence and lifestyle interventions

• Microbiome, metabolomics, and multi-omics analytics platforms

• Dietary supplement testing, formulation, and bioavailability evaluation technologies

• Real-world evidence and longitudinal outcomes research platforms

• Cardiovascular, sleep, and metabolic disease prevention technologies

• Cancer prevention and survivorship intervention systems related to GLP-1 use

• Aging, cognitive health, and neurodegenerative disease research platforms

• Musculoskeletal, bone density, sarcopenia, and fracture risk monitoring technologies

• Oral health, ocular health, and inflammatory response assessment systems

• Behavioral health, appetite regulation, and satiety analytics platforms

• Drug interaction and safety assessment technologies for GLP-1 mimetics

• Clinical decision support systems integrating nutrition and metabolic biomarkers

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, laboratory testing, nutritional analysis, wearable integration, clinical research, bioinformatics analysis, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare, nutrition, or biotechnology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: School Mental and Behavioral Health: Expanding Access to Evidence-Based Interventions and Services

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on expanding access to evidence-based mental and behavioral health interventions in school and afterschool settings. This highlighted topic supports multidisciplinary projects aimed at improving prevention, screening, intervention delivery, implementation, and long-term sustainability of school-based mental health services for children and adolescents.

NIH recognizes that schools often serve as primary access points for healthcare and mental health services, particularly in underserved communities. The initiative is particularly interested in scalable, research-informed approaches that can be rapidly deployed using existing school infrastructure, school personnel, behavioral health providers, and community partnerships.

Companies developing school mental health technologies, AI-enabled risk screening platforms, behavioral health analytics systems, telehealth solutions, decision support tools, digital therapeutics, student engagement platforms, implementation science technologies, or care coordination systems may be strong candidates for funding.

Areas of interest include mental health risk identification, intervention matching systems, multitiered support frameworks (MTSS), behavioral health decision support tools, substance use prevention, implementation science, fidelity monitoring, workforce training, community-engaged intervention models, and scalable school-based service delivery systems. NIH is also encouraging projects focused on health equity, workforce shortages, youth participatory research, and sustainable implementation models that improve access to care for vulnerable student populations.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and implementation impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including NIMH, NIDA, NINR, NIAAA, NIMHD, ODP, and ORWH, all of which are seeking scalable innovations that improve school-based mental health care delivery, behavioral health prevention, implementation science, and long-term student well-being.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of school mental health technologies, behavioral health intervention platforms, digital therapeutics, screening systems, and implementation science solutions.

Eligible activities may include:

• AI and machine learning platforms for student mental health risk screening

• School-based behavioral health assessment and monitoring systems

• Digital therapeutics and mental health intervention platforms

• Telehealth and virtual behavioral healthcare delivery technologies

• Decision support tools for matching students to interventions and services

• Substance use prevention and early intervention technologies

• Multitiered system of supports (MTSS) implementation platforms

• School-based care coordination and referral management systems

• Workforce training, supervision, and credentialing technologies

• Behavioral health implementation science and fidelity monitoring systems

• Student engagement and wellness support applications

• Community-engaged and youth participatory intervention technologies

• Mental health analytics and outcomes tracking platforms

• Equity-focused and culturally responsive behavioral health solutions

• Nurse-led and school staff-delivered intervention systems

• School-community partnership and integrated care delivery platforms

• Prototype development, implementation studies, and clinical validation research

• Commercialization planning, scalability testing, and regulatory preparation activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, implementation research, telehealth deployment, behavioral health analytics, school systems integration, stakeholder engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable school mental health or healthcare technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Tackling Acquisition of Language in Kids (TALK)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding, evaluating, and improving outcomes for children with late language emergence, commonly referred to as “late talking.” This highlighted topic supports multidisciplinary research aimed at advancing knowledge of early language development trajectories, identifying predictive factors for long-term outcomes, and developing more effective interventions and support systems for children experiencing language delays.

Late talking affects approximately 10% to 20% of children and may occur alongside conditions such as autism, speech-motor disorders, sensory disorders, developmental disabilities, or without any known underlying condition. NIH is particularly interested in projects that improve understanding of developmental variability, language recovery pathways, persistent language disorders, and the impact of social, cultural, and environmental factors on communication outcomes.

Companies developing speech and language technologies, AI-enabled developmental assessment platforms, digital therapeutics, augmentative and alternative communication (AAC) tools, predictive analytics systems, educational technologies, caregiver support platforms, or longitudinal child development analytics solutions may be strong candidates for funding.

Areas of interest include longitudinal developmental tracking, predictive modeling, early identification tools, culturally responsive interventions, developmental trajectory analysis, communication assessment technologies, caregiver guidance systems, implementation science, and novel approaches to supporting communication success in children with diverse developmental needs. NIH is also encouraging projects leveraging existing datasets, AI and machine learning, telehealth delivery systems, and scalable digital interventions to improve clinical and community-based support for late-talking children.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on funding and commercialization support depending on project scope and translational impact.

This highlighted topic is supported primarily by the National Institute on Deafness and Other Communication Disorders (NIDCD) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both of which are seeking transformative innovations that improve childhood language development, developmental trajectory prediction, communication interventions, and long-term developmental outcomes.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of speech and language technologies, developmental assessment tools, AI analytics platforms, AAC systems, and child development intervention solutions related to late talking and language development.

Eligible activities may include:

• AI and machine learning platforms for language development prediction and assessment

• Speech and language screening and diagnostic technologies

• Longitudinal developmental tracking and analytics systems

• Augmentative and alternative communication (AAC) technologies

• Digital therapeutics and communication intervention platforms

• Telehealth and remote speech-language therapy systems

• Caregiver guidance, education, and support technologies

• Developmental trajectory modeling and predictive analytics tools

• Autism, speech-motor, sensory, and developmental disability communication support systems

• Culturally and linguistically responsive language assessment platforms

• Educational technologies supporting early language acquisition

• Natural language processing (NLP) tools for child communication analysis

• Early identification and intervention systems for language disorders

• Clinical decision support and personalized treatment planning platforms

• Community-based and school-based language support technologies

• Data integration and enrichment tools for developmental research datasets

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, implementation scaling, and regulatory preparation activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, speech analytics, telehealth deployment, developmental research, data analysis, caregiver engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable pediatric health or communication technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Characterizing Interactions between Biology and Electromagnetic Radiation

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding how low-intensity electromagnetic radiation (EMR) interacts with biological systems across therapeutic, environmental, and physiological contexts. This highlighted topic supports multidisciplinary research aimed at characterizing both the beneficial and potentially harmful effects of electromagnetic radiation exposure while advancing technologies that improve EMR sensing, imaging, dosimetry, delivery, and safety assessment.

NIH is particularly interested in projects exploring how optical, electric, magnetic, radiofrequency, ultraviolet, and other forms of electromagnetic radiation influence biological processes such as inflammation, tissue regeneration, mitochondrial function, blood flow, cellular repair, neural activity, and immune responses. Companies developing EMR-based therapeutics, bioelectronic medicine platforms, AI-enabled dosimetry systems, sensing technologies, imaging systems, computational modeling platforms, wearable exposure monitoring devices, or quantum-enabled biomedical technologies may be strong candidates for funding.

Areas of interest include personalized EMR therapies, therapeutic field optimization, environmental exposure analysis, AI-assisted EMR transport modeling, tissue-level dosimetry, exposure-response characterization, quantum sensing technologies, wearable exposure analytics, and safety assessment frameworks. NIH is also encouraging projects investigating EMR exposure from environmental sources such as cell phones, Wi-Fi routers, wearables, ultraviolet light, and cell towers, including studies focused on developmental susceptibility, exposomics, genetic and epigenetic response variability, and long-term health effects.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported primarily by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Institute of Environmental Health Sciences (NIEHS), both of which are seeking transformative innovations that improve EMR-based therapeutics, environmental exposure science, computational modeling, biomedical sensing, and human health outcomes.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of EMR-based technologies, biomedical sensing systems, computational modeling platforms, imaging tools, and environmental exposure analytics solutions.

Eligible activities may include:

• AI and machine learning platforms for EMR dosimetry and exposure modeling

• EMR sensing, imaging, and delivery technologies

• Bioelectronic medicine and electromagnetic therapeutic platforms

• Quantum-enabled biomedical sensing and measurement systems

• Wearable EMR monitoring and exposure assessment devices

• Computational biology and tissue transport simulation platforms

• Personalized EMR treatment optimization technologies

• Environmental exposure and exposome analytics systems

• Therapeutic electromagnetic field delivery and targeting systems

• Optical, electric, and magnetic field therapeutic technologies

• Cell phone, Wi-Fi, wearable, and radiofrequency exposure assessment tools

• Genetic and epigenetic response modeling related to EMR exposure

• Imaging and tissue-level perfusion monitoring systems

• Inflammation, regeneration, and mitochondrial function analysis technologies

• Safety monitoring, adverse effect detection, and risk stratification platforms

• Digital twins and predictive biomedical simulation systems

• Prototype development, translational studies, and validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, laboratory testing, biomedical imaging research, computational modeling, wearable integration, exposure analytics, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare, bioengineering, or environmental health technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Computational Modeling of Complex Processes Across Biological Scales

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on computational modeling of complex biological processes across multiple spatial and temporal scales. This highlighted topic supports multidisciplinary projects developing advanced multiscale computational models that integrate molecular, cellular, tissue, organ, organismal, behavioral, and population-level processes to improve understanding of human health and disease.

NIH is particularly interested in projects that improve the rigor, reproducibility, transparency, interoperability, and reusability of computational multiscale models while fostering collaborative modeling communities across biomedical disciplines. Companies developing AI-enabled modeling platforms, systems biology software, digital twin technologies, computational biology tools, biomedical simulation systems, cloud-based modeling infrastructure, or advanced predictive analytics platforms may be strong candidates for funding.

Areas of interest include infectious disease modeling, cancer systems biology, cardiovascular and pulmonary modeling, neuroscience simulation, aging and Alzheimer’s disease research, autoimmune disease modeling, substance use disorder modeling, precision medicine, microbiome dynamics, organ-system interactions, and Novel Alternative Methods (NAMs) for therapeutic development and safety assessment. NIH is also encouraging projects integrating AI, machine learning, FAIR data practices, uncertainty quantification, cloud-native infrastructure, and interoperable data science workflows.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by numerous NIH Institutes and Offices including NIAID, NCI, NHLBI, NIA, NIMH, NIDA, NIBIB, NLM, NIDCR, NCCIH, ORWH, and ODSS, all of which are seeking transformative innovations that improve computational modeling, biomedical simulation, translational research, and precision health outcomes.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of computational biology platforms, AI-enabled simulation systems, multiscale modeling infrastructure, and biomedical data science technologies.

Eligible activities may include:

• AI and machine learning platforms for multiscale biological modeling

• Computational biology and systems biology software development

• Digital twin and predictive simulation technologies

• Biomedical modeling infrastructure and cloud-native computational platforms

• FAIR data integration, interoperability, and reproducibility systems

• Cancer, infectious disease, cardiovascular, neurological, and autoimmune disease modeling tools

• Precision medicine and personalized health prediction platforms

• Organ-system and brain-body interaction simulation technologies

• Aging, Alzheimer’s disease, and lifespan modeling systems

• Novel Alternative Methods (NAMs) for therapeutic testing and safety evaluation

• Biomarker discovery and predictive analytics platforms

• Computational neuroscience and neural circuit simulation systems

• Microbiome, immunology, and host-environment interaction models

• Population health, epidemiological, and behavioral systems modeling

• Biomedical imaging integration and quantitative uncertainty analysis tools

• Open-source computational workflow and model-sharing infrastructure

• Prototype development, translational studies, and validation research

• Commercialization planning, regulatory preparation, and scale-up activities

Funding may also support personnel, software engineering, cloud computing infrastructure, AI model development, computational simulation research, data harmonization, bioinformatics analysis, systems biology validation studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable computational biology or healthcare technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Advancing Childhood and Adolescent & Young Adult (AYA) Cancer Research

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on accelerating childhood, adolescent, and young adult (AYA) cancer research across the full continuum of prevention, diagnosis, treatment, survivorship, and long-term care. This highlighted topic supports multidisciplinary projects designed to improve understanding of pediatric and AYA cancer biology while advancing precision medicine, AI-enabled analytics, therapeutic development, and patient-centered care approaches.

NIH is particularly interested in projects addressing the unique challenges associated with pediatric and AYA cancers, including rare disease subtypes, limited patient populations, lack of robust preclinical models, treatment-related toxicities, fragmented datasets, and disparities in access to specialized care and clinical trials. Companies developing AI and machine learning platforms, pediatric oncology diagnostics, precision medicine technologies, clinical analytics systems, digital health platforms, survivorship monitoring tools, or decentralized clinical trial infrastructure may be strong candidates for funding.

Areas of interest include multi-omics analysis, AI-ready data infrastructure, fusion-driven cancer biology, synthetic lethality approaches, immunotherapy, tumor microenvironment research, treatment resistance, decentralized clinical trials, survivorship studies, prevention of treatment-related toxicities, and long-term quality-of-life monitoring. NIH is also encouraging projects focused on oral and craniofacial cancer complications, healthcare access, and integration of real-world evidence and electronic health record (EHR) data into pediatric cancer research.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported primarily by the National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR), and the Office of Disease Prevention (ODP), all of which are seeking transformative innovations that improve pediatric and AYA cancer prevention, diagnosis, treatment outcomes, survivorship, and quality of life.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of pediatric oncology technologies, AI platforms, diagnostics, therapeutics, clinical analytics systems, and survivorship care solutions.

Eligible activities may include:

• AI and machine learning platforms for pediatric and AYA cancer research

• Multi-omics data integration and predictive analytics systems

• Precision oncology diagnostics and biomarker discovery technologies

• Fusion-driven cancer and synthetic lethality therapeutic platforms

• Immunotherapy and tumor microenvironment research technologies

• Pediatric cancer imaging, pathology, and molecular analysis systems

• Decentralized clinical trial infrastructure and patient recruitment technologies

• Survivorship monitoring and long-term toxicity assessment platforms

• Digital health and remote patient monitoring tools for pediatric oncology

• Clinical decision support and treatment optimization systems

• Real-world evidence and EHR-integrated oncology analytics platforms

• Preclinical cancer models, organoids, and translational research systems

• Oral, dental, and craniofacial oncology technologies and treatment monitoring tools

• Prevention and mitigation technologies for treatment-related side effects

• Healthcare access and continuity-of-care platforms for pediatric cancer patients

• Data harmonization and AI-ready pediatric oncology research infrastructure

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, software engineering, cloud computing infrastructure, AI model development, genomic sequencing, laboratory testing, bioinformatics analysis, clinical trial preparation, survivorship research, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable pediatric oncology or healthcare technology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Training and Career Development in Dissemination and Implementation Science

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research training and career development proposals focused on dissemination and implementation (D&I) science. This highlighted topic supports projects designed to strengthen the biomedical and public health workforce by building expertise in how evidence-based innovations (EBIs) are effectively adopted, integrated, scaled, and sustained across clinical, community, and healthcare settings.

NIH recognizes that many proven healthcare interventions fail to achieve broad real-world impact due to barriers in implementation, adoption, scalability, and sustainability. This initiative seeks to advance D&I science through training programs, career development pathways, methodological innovation, and interdisciplinary research capacity building across a wide range of health specialties and populations.

Companies and organizations developing implementation science platforms, healthcare workforce training technologies, AI-enabled research tools, digital learning systems, clinical analytics platforms, healthcare quality improvement technologies, community engagement systems, or implementation evaluation software may be strong candidates for funding.

Areas of interest include dissemination and implementation frameworks, hybrid effectiveness-implementation trials, community-engaged research, pragmatic clinical trial design, qualitative and mixed methods research, human-centered design, adaptation measurement, implementation analytics, healthcare scalability models, and health disparities reduction strategies. NIH is also encouraging projects focused on implementation science for mental health, substance use, genomics, chronic disease management, HIV care, sensory disorders, neurological disease, and complementary health interventions.

Funding is available through multiple NIH training and career development mechanisms, including Fellowships, Career Development Awards, Institutional Training Grants, and Education Projects, with opportunities for translational and workforce-focused implementation science support depending on project scope and alignment.

This highlighted topic is supported by numerous NIH Institutes and Offices including NIDCD, NCCIH, NHGRI, NIDA, NIDDK, NIMH, NINDS, NINR, NCI, OAR, ODP, and others, all of which are seeking scalable innovations that strengthen dissemination and implementation science capacity, workforce development, and evidence-based healthcare adoption.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of dissemination and implementation (D&I) science training platforms, workforce development technologies, healthcare adoption systems, and implementation analytics tools.

Eligible activities may include:

• Digital training and workforce development platforms for D&I science

• AI and machine learning systems for implementation analytics and healthcare adoption

• Community-engaged research and stakeholder collaboration technologies

• Hybrid effectiveness-implementation trial infrastructure

• Human-centered design and healthcare implementation tools

• Qualitative and mixed methods research platforms

• Clinical decision support and evidence-based practice integration systems

• Healthcare scalability, sustainability, and adoption analytics

• Research-practice partnership and collaboration platforms

• Dissemination strategy development and communication technologies

• Implementation outcome measurement and fidelity tracking systems

• Health disparities reduction and equitable care implementation tools

• Telehealth and digital health implementation research platforms

• Genomics, mental health, HIV, neurology, and chronic disease implementation technologies

• Healthcare quality improvement and organizational change management systems

• Community-based intervention delivery and engagement technologies

• Prototype development, pilot implementation studies, and translational research

• Commercialization planning, implementation scaling, and dissemination activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, healthcare systems integration, implementation research, training curriculum development, data analytics, community engagement, intellectual property protection, and commercialization activities necessary to advance a scalable and commercially viable healthcare, education, or implementation science solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Advancing Mechanism-driven Translational Research of Beneficial and Detrimental Effect of Psilocybin on Cancer and Other Health Conditions

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing mechanism-driven translational research into both the beneficial and detrimental effects of psilocybin on cancer and other health conditions. This highlighted topic supports rigorous human-relevant studies designed to improve scientific understanding of psilocybin’s biological activity, therapeutic potential, safety profile, and long-term health impacts.

NIH is particularly interested in projects investigating molecular pathways, receptor interactions, biomarkers, pharmacology, neurobiology, and translational models that can inform future clinical trial design and evidence-based human use. Companies developing psychedelic therapeutics, AI-enabled biomarker platforms, digital therapeutics, neuropharmacology technologies, translational drug development systems, computational biology tools, or precision medicine platforms may be strong candidates for funding.

Areas of interest include psilocybin’s effects on cancer therapeutics, pain management, mental health, neuroplasticity, substance use disorders (SUDs), chronic use and microdosing, pharmacokinetics, host genetics, immune modulation, and interactions with standard-of-care therapies. NIH is also encouraging projects focused on novel psilocybin analogs, human-relevant disease models, AI-enabled analytics, and translational research technologies capable of improving therapeutic precision and risk mitigation.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by the National Cancer Institute (NCI), National Center for Complementary and Integrative Health (NCCIH), and National Institute on Drug Abuse (NIDA), all of which are seeking transformative innovations that improve understanding, safety, therapeutic development, and evidence-based use of psilocybin and related compounds.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of psychedelic therapeutics, translational research technologies, biomarkers, computational tools, and precision medicine systems related to psilocybin research.

Eligible activities may include:

• Psilocybin therapeutic development and translational drug discovery

• AI and machine learning platforms for psychedelic biomarker analysis

• Neuropharmacology and neuroplasticity research technologies

• Precision medicine and patient stratification systems

• Clinical decision support and dosing optimization platforms

• Human-relevant disease models and translational research systems

• Computational biology and systems pharmacology tools

• Biomarker discovery and predictive analytics technologies

• Pain management and symptom burden intervention platforms

• Substance use disorder (SUD) therapeutic development technologies

• Psilocybin analog, prodrug, and modified compound development

• Pharmacokinetic and safety profiling technologies

• Digital therapeutics and behavioral intervention integration systems

• Immune, tumor, and neurological response analysis platforms

• Cancer symptom management and supportive care technologies

• Longitudinal monitoring systems for chronic use and microdosing studies

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, laboratory testing, medicinal chemistry, AI model development, software engineering, cloud infrastructure, clinical trial preparation, bioinformatics analysis, preclinical studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable biotechnology or therapeutic solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Enhancing the IMPROVE-funded Maternal Health Centers of Excellence

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging supplemental research proposals that enhance and expand the IMPROVE-funded Maternal Health Research Centers of Excellence and Hubs. This highlighted topic supports projects designed to accelerate research and innovation aimed at reducing maternal morbidity and mortality, particularly in underserved regions and populations with disproportionately poor maternal health outcomes.

The initiative is part of the NIH Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone (IMPROVE) Initiative and seeks to strengthen ongoing maternal health research through expanded geographic reach, collaborative partnerships, and integration of emerging maternal health technologies. NIH is especially interested in projects that expand research into maternity care deserts and regions with high rates of maternal mortality and severe maternal morbidity.

Companies developing maternal health technologies, remote patient monitoring systems, digital health platforms, AI-enabled maternal risk prediction tools, telehealth infrastructure, wearable devices, pregnancy monitoring technologies, clinical analytics systems, or healthcare coordination platforms may be strong candidates for funding.

Areas of interest include maternal mortality prevention, pregnancy-related complication monitoring, rural and underserved healthcare delivery, collaborative maternal health research networks, digital diagnostics, remote monitoring, and integration of technologies developed through the RADx maternal health challenge. NIH is also encouraging scalable technologies and interventions that improve maternal outcomes, access to care, and longitudinal pregnancy health monitoring.

Funding is available through the NIH SBIR/STTR Program and related NIH supplemental funding mechanisms, with opportunities for both translational research and commercialization support depending on project scope and alignment with existing IMPROVE-funded Centers and Hubs.

This highlighted topic is supported primarily by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which is seeking transformative innovations that improve maternal healthcare access, clinical outcomes, and implementation of advanced maternal health technologies.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of maternal health technologies, remote monitoring systems, clinical analytics platforms, and healthcare delivery solutions designed to reduce maternal morbidity and mortality.

Eligible activities may include:

• Remote maternal monitoring and wearable pregnancy technologies

• AI and machine learning platforms for maternal risk prediction

• Telehealth systems for prenatal and postpartum care

• Digital diagnostics and point-of-care maternal health technologies

• Healthcare coordination and maternal care navigation platforms

• Expansion of maternal health programs into maternity care deserts

• Pregnancy complication monitoring and early warning systems

• Clinical decision support systems for maternal healthcare providers

• Integration of RADx maternal health technologies into care delivery

• Population health analytics and maternal outcomes tracking systems

• Community-based maternal health intervention technologies

• Longitudinal pregnancy and postpartum monitoring platforms

• Rural maternal healthcare access and infrastructure technologies

• Collaborative maternal health data-sharing and interoperability systems

• Equity-focused maternal health implementation and outreach platforms

• Prototype development, implementation studies, and translational research

• Commercialization planning, regulatory preparation, and scale-up activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, wearable integration, clinical validation studies, telehealth deployment, healthcare systems integration, community engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable maternal health solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Accelerating Hidradenitis Suppurativa Research

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on accelerating scientific understanding, diagnostics, predictive tools, and therapeutic development for Hidradenitis Suppurativa (HS). This highlighted topic supports multidisciplinary research designed to better understand the molecular, immunological, genetic, microbial, hormonal, metabolic, and environmental mechanisms driving HS development, progression, and disease flares.

HS is a chronic inflammatory skin disease affecting between 1% and 4% of the population and is associated with significant comorbidities including obesity, metabolic syndrome, hypertension, anxiety, and depression. NIH is particularly interested in projects that improve understanding of HS endotypes, inflammatory pathways, microbiome interactions, immune dysregulation, and environmental triggers while advancing precision diagnostics and targeted treatment strategies.

Companies developing dermatology diagnostics, AI-enabled predictive models, biomarker platforms, wearable health technologies, imaging systems, immunology tools, microbiome analytics, digital health platforms, or novel therapeutic technologies may be strong candidates for funding.

Areas of interest include immune signaling pathways, cytokine dysregulation, microbiome and biofilm interactions, genetic and exposome analysis, predictive analytics, wearable monitoring systems, point-of-care diagnostics, New Approach Methodologies (NAMs), clinical trial readiness platforms, and innovative translational research models. NIH is also encouraging development of common data elements (CDEs), sex-specific analyses, and collaborative research frameworks that improve future clinical trial execution and patient outcomes.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on funding and commercialization support depending on project scope and translational impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including the Office of Research on Women’s Health (ORWH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and National Institute of Environmental Health Sciences (NIEHS), all of which are seeking transformative innovations that improve HS diagnosis, treatment, translational research, and patient quality of life.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of diagnostics, biomarkers, predictive analytics platforms, therapeutics, digital health tools, and translational research technologies related to Hidradenitis Suppurativa (HS).

Eligible activities may include:

• AI and machine learning platforms for HS diagnosis and flare prediction

• Biomarker discovery and precision dermatology technologies

• Point-of-care diagnostics and wearable monitoring systems

• Imaging and digital dermatology assessment platforms

• Immunology and inflammatory pathway research technologies

• Microbiome, biofilm, and exposome analysis systems

• Computational biology and predictive modeling tools

• Genetic and epigenetic analysis platforms for HS research

• Digital health and remote patient monitoring technologies

• New Approach Methodologies (NAMs), organoids, and in vitro disease models

• Therapeutic target identification and translational drug development

• Clinical trial readiness tools and common data element (CDE) development

• Personalized medicine and sex-specific treatment approaches

• Environmental exposure and toxicology research platforms

• Omics analysis and systems biology technologies

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, laboratory testing, software engineering, AI model development, cloud infrastructure, bioinformatics analysis, preclinical studies, microbiome research, wearable integration, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable dermatology or biotechnology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Advancing Toward a Cure for Acquired Neuropathy

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing disease-modifying therapies, biomarkers, diagnostics, and clinical outcome measures for acquired neuropathy (AN). This highlighted topic supports multidisciplinary research aimed at improving understanding of neuropathy pathophysiology and accelerating the development of interventions capable of preventing, slowing, or reversing nerve damage associated with inflammatory, autoimmune, diabetic, and cancer-related neuropathies.

NIH is particularly interested in projects targeting major unmet needs in acquired neuropathy research, including biomarker discovery, improved clinical assessment tools, and regenerative or neuroprotective therapeutics. Companies developing neuromodulation technologies, AI-enabled diagnostics, biomarker analytics platforms, regenerative medicine solutions, digital health tools, peripheral nerve therapies, or advanced neurodiagnostic systems may be strong candidates for funding.

Areas of interest include diabetic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), autoimmune neuropathies, autonomic dysfunction, regenerative medicine, translational disease models, predictive analytics, wearable diagnostics, clinical monitoring systems, and novel therapeutic screening platforms. NIH is also encouraging projects that address disease heterogeneity, sex differences, socioeconomic influences, and personalized approaches to neuropathy treatment and monitoring.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported primarily by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), and the Office of Research on Women’s Health (ORWH), all of which are seeking transformative innovations that improve acquired neuropathy diagnosis, monitoring, treatment, and patient outcomes.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of diagnostics, biomarkers, therapeutics, neuromodulation systems, regenerative medicine technologies, and clinical monitoring tools related to acquired neuropathy.

Eligible activities may include:

• Biomarker discovery and predictive analytics platforms for neuropathy detection

• AI and machine learning tools for neuropathy diagnosis and progression monitoring

• Regenerative medicine and neuroprotective therapeutic development

• Neuromodulation and peripheral nerve stimulation technologies

• Clinical outcome measurement and digital assessment systems

• Wearable devices and remote monitoring technologies for neuropathy patients

• Translational animal models and organoid-based neuropathy research systems

• Therapeutics for diabetic neuropathy and autonomic neuropathy

• Chemotherapy-induced peripheral neuropathy (CIPN) prevention and treatment technologies

• Autoimmune neuropathy therapeutic platforms

• Computational biology and bioinformatics tools for neuropathy research

• Personalized medicine approaches for neuropathy management

• Imaging and diagnostic systems for peripheral nerve function assessment

• Drug screening and therapeutic validation platforms

• Pain management and sensory function monitoring technologies

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, laboratory testing, software engineering, AI model development, cloud infrastructure, biomarker analysis, preclinical studies, wearable integration, bioinformatics pipelines, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable neurology or biotechnology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Advancing Research into the Cause and Treatment of Rare Skin Diseases

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing the understanding, diagnosis, and treatment of rare skin diseases through multidisciplinary basic, translational, and clinical research. This highlighted topic supports projects aimed at uncovering disease mechanisms, identifying therapeutic targets, improving diagnostics, and accelerating the development of novel treatments for rare dermatological conditions that currently lack effective therapies.

NIH is particularly interested in projects investigating the genetic, molecular, cellular, and environmental factors contributing to rare skin diseases, many of which present in childhood and have limited or no FDA-approved treatment options. Companies developing dermatology therapeutics, gene therapies, AI-enabled diagnostics, biomarker technologies, organoid models, computational biology platforms, precision medicine systems, or regenerative medicine solutions may be strong candidates for funding.

Areas of interest include genetic studies, biomarker discovery, environmental exposure research, disease modeling, organoids and organ-on-chip systems, drug repurposing, gene editing, cell therapies, revertant mosaicism research, and therapeutics targeting shared molecular disease mechanisms across multiple rare skin disorders. NIH is also encouraging projects using New Approach Methodologies (NAMs), computational modeling, and translational platform technologies that can accelerate drug discovery and therapeutic development.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), National Institute of Environmental Health Sciences (NIEHS), and the Office of Research on Women’s Health (ORWH), all of which are seeking transformative innovations that improve rare skin disease diagnosis, therapeutics, translational research, and patient outcomes.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of therapeutics, diagnostics, computational tools, disease models, and translational research platforms related to rare skin diseases.

Eligible activities may include:

• Gene therapy and gene editing technologies for rare skin diseases

• AI and machine learning platforms for dermatology diagnostics and biomarker discovery

• Cell therapy and regenerative medicine approaches

• Organoid, 3D tissue culture, and organ-on-chip disease modeling systems

• Computational biology and precision medicine platforms

• Biomarker discovery and disease progression monitoring technologies

• Drug repurposing and therapeutic screening systems

• Molecular and cellular pathway analysis tools

• Environmental exposure and exposome research technologies

• Translational platform technologies applicable across multiple rare diseases

• Basket trial infrastructure and shared molecular etiology therapeutic development

• Dermatology imaging and digital pathology systems

• Personalized medicine and genomic diagnostic platforms

• High-throughput drug screening and toxicology testing systems

• Autoimmune-associated skin disease therapeutic technologies

• Revertant mosaicism and disease reversal research platforms

• Prototype development, translational studies, and clinical validation research

• Commercialization planning, regulatory preparation, and manufacturing scale-up activities

Funding may also support personnel, laboratory testing, software engineering, AI model development, cloud infrastructure, genomic sequencing, bioinformatics analysis, preclinical studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable dermatology or biotechnology solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Advancing “Science of Science” Research to Understand and Strengthen the Biomedical Research Ecosystem

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing the “science of science” — a growing field dedicated to understanding and strengthening the biomedical research ecosystem. This highlighted topic supports multidisciplinary projects that analyze how scientific discoveries are generated, translated, funded, disseminated, reproduced, commercialized, and sustained across biomedical research systems and institutions.

NIH is particularly interested in projects that improve the efficiency, rigor, reproducibility, collaboration, workforce development, and commercialization outcomes of biomedical research. Companies developing research analytics platforms, AI-enabled scientific evaluation tools, workforce development technologies, collaboration software, data-sharing infrastructure, innovation measurement systems, or translational research optimization platforms may be strong candidates for funding.

Areas of interest include biomedical workforce development, team science, research reproducibility, data standardization, innovation analytics, translational bottleneck analysis, commercialization outcomes, research capacity building, AI and data science adoption, biomedical informatics, scientific collaboration networks, and economic impact assessment of research investments. NIH is also encouraging projects that strengthen underfunded research institutions, expand participation in biomedical research, and improve translational pathways from discovery to patient impact.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and implementation impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including NIGMS, NLM, NIA, NIAID, NIBIB, NIDCR, NIMHD, NEI, ODSS, ORWH, and OBSSR, all of which are seeking scalable innovations that improve the effectiveness, sustainability, rigor, and impact of the biomedical research enterprise.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of scientific analytics platforms, biomedical workforce technologies, research infrastructure systems, collaboration tools, and translational research optimization solutions.

Eligible activities may include:

• AI and machine learning platforms for research analytics and scientific evaluation

• Research reproducibility and scientific integrity monitoring systems

• Biomedical workforce development and training technologies

• Team science and interdisciplinary collaboration platforms

• Translational research optimization and commercialization analytics

• Data standardization, interoperability, and sharing infrastructure

• Research productivity and innovation measurement tools

• Scientific collaboration network analysis platforms

• Biomedical informatics and research data science technologies

• Economic impact and return-on-investment analysis systems for research funding

• Predictive analytics for scientific innovation and translational success

• Research capacity building technologies for underfunded institutions

• Health disparities and inclusive workforce development solutions

• Scientific publishing, peer review, and research dissemination tools

• AI-enabled tools supporting biomedical informatics and health AI adoption

• Workforce recruitment, retention, and career progression analytics

• Prototype development, translational studies, and implementation research

• Commercialization planning, regulatory preparation, and scale-up activities

Funding may also support personnel, software engineering, cloud computing infrastructure, AI model development, data analytics, implementation research, collaboration systems development, workforce training programs, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable research technology or analytics solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

NIH Highlighted Topic: Implementation Science to Optimize HIV Prevention and Treatment

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on implementation science strategies that improve the delivery, adoption, scale-up, and sustainability of HIV prevention and treatment interventions across real-world healthcare and community settings. This highlighted topic supports multidisciplinary projects aimed at closing the gap between proven HIV interventions and their successful implementation in diverse populations and care environments.

NIH is particularly interested in projects that optimize uptake of biomedical HIV prevention and treatment tools, including long-acting therapies, behavioral interventions, telehealth solutions, integrated care delivery models, and evidence-based HIV care practices. Companies developing digital health platforms, AI-enabled care coordination systems, remote monitoring technologies, patient engagement platforms, implementation analytics tools, telehealth infrastructure, or community-based healthcare technologies may be strong candidates for funding.

Areas of interest include HIV prevention implementation, treatment adherence, viral suppression strategies, aging with HIV, HIV and cancer care coordination, substance use disorder interventions, women’s health, rural healthcare delivery, behavioral health integration, healthcare systems optimization, implementation scalability, and community-led intervention models. NIH is also encouraging projects leveraging artificial intelligence, machine learning, natural language processing (NLP), electronic health records, geospatial technologies, and predictive analytics to improve care delivery and public health outcomes.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on funding and commercialization support depending on project scope and implementation impact.

This highlighted topic is supported by numerous NIH Institutes and Offices including OAR, NIAID, NIMH, NLM, NIDA, NIA, NCI, NINR, ORWH, NIDDK, NIDCR, NIMHD, and others, all of which are seeking scalable innovations that improve HIV prevention, treatment adherence, integrated care delivery, and long-term health outcomes in real-world settings.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, implementation, and commercialization of HIV prevention technologies, digital health systems, implementation science platforms, and integrated care delivery solutions.

Eligible activities may include:

• Digital health and telehealth platforms for HIV prevention and treatment

• AI and machine learning systems for treatment adherence and care optimization

• Long-acting HIV therapeutic delivery and monitoring technologies

• Remote patient monitoring and wearable health systems

• Clinical decision support and healthcare workflow management platforms

• Community-based HIV prevention and care coordination technologies

• Behavioral health and substance use disorder intervention systems

• HIV implementation science analytics and scalability platforms

• EHR integration, interoperability, and health data exchange tools

• Natural language processing (NLP) and predictive analytics for HIV care

• Patient engagement and viral suppression support technologies

• Women’s health and female-specific HIV prevention technologies

• Rural healthcare delivery and mobile care platforms

• HIV and oncology integrated care coordination systems

• Community-led and multi-sector intervention delivery platforms

• Population health analytics and implementation research infrastructure

• Prototype development, implementation trials, and translational studies

• Commercialization planning, regulatory preparation, and scale-up activities

Funding may also support personnel, software engineering, cloud infrastructure, AI model development, clinical implementation research, health systems integration, telehealth deployment, community engagement, data analytics, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare or digital health solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

• Government Validation and Credibility:
  Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

• Enhanced Visibility and Market Recognition:
  Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

• Access to the Federal Innovation Ecosystem:
  Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

• Stronger Commercial and Exit Potential:
  By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

• Are organized for profit with a U.S. place of business.

• Have ≤ 500 employees including affiliates.

• Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

• A clear unmet medical or public-health need,

• Strong scientific rationale and feasibility,

• High commercialization potential, supported by a realistic market and regulatory strategy, and

• Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

• Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

• Foreign entities are not eligible.

• Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.